With medical marijuana programs now established across numerous U.S. states, the scientific community is only beginning to uncover the vast therapeutic potential locked within the cannabis plant.
THC: The Well-Known Cannabinoid With Proven Medical Applications
Tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, has long been recognized for its palliative effects. Whether consumed through smoking or the increasingly preferred method of vaporization — which heats plant material to release active compounds without combustion — THC provides measurable relief for pain, anxiety, nausea, and appetite loss. Clinical evidence supports its use against glaucoma, epilepsy, and a range of other conditions.
THC works by activating cannabinoid receptors concentrated in brain regions associated with pleasure, memory, concentration, and time perception. This activation produces the characteristic euphoric sensation users describe as being “high.”
CBD: The Non-Psychoactive Cannabinoid Emerging as a Medical Powerhouse
Research conducted primarily outside the United States has built a growing consensus that cannabidiol (CBD) — a non-psychoactive compound found in raw, unheated cannabis leaves — may offer therapeutic benefits that far exceed those of THC alone. Unlike THC, CBD does not produce intoxication and actually counteracts some of THC’s effects, such as suppressing appetite rather than stimulating it.
Certain cannabis strains contain high levels of CBD alongside smaller amounts of THC, a combination some researchers believe enhances the plant’s overall healing potential through what is sometimes called the “entourage effect.”
Groundbreaking Cancer Research With CBD
At the California Pacific Medical Center, researchers Sean D. McAllister and Pierre Desprez conducted landmark studies examining CBD’s impact on cancer cells. Their findings suggested that non-psychoactive cannabis compounds could eventually position chemotherapy and radiation as secondary treatment options rather than first-line approaches. In subsequent research, McAllister and Desprez reported that CBD demonstrated the ability to prevent breast cancer metastasis.
Dr. Donald Abrams, a cancer specialist and professor of integrative medicine at the University of California, San Francisco, has tracked cannabis research for decades. He notes that the National Cancer Institute actively investigated cannabinoids during the 1970s, but federal restrictions on cannabis research effectively drove that work overseas to countries including Israel, Spain, and Italy. According to Abrams, existing international studies reveal CBD’s remarkable capacity to arrest cancer cell division, migration, metastasis, and invasiveness.
Promising Results Against Alzheimer’s Disease
CBD research extends well beyond oncology. A 2006 study published in Molecular Pharmaceutics by University of Connecticut researchers found that cannabis-derived compounds were considerably better at suppressing the abnormal clumping of malformed proteins — a hallmark of Alzheimer’s disease — than any prescription medication available at the time. The team predicted that cannabinoid-based treatments would become breakthrough therapies in the near future.
Cannabis Medicine Through History: 6,000 Years of Documented Use
The therapeutic use of cannabis stretches back roughly 6,000 years, with origins in India before spreading to China and the Middle East. The plant arrived in Western medicine during the 1800s and was listed in the U.S. Pharmacopeia until the 1930s. Prescribed for over 100 ailments, cannabis appeared in cough remedies, analgesics, and tonics available at local pharmacies and through mail-order catalogs from companies like Sears, Roebuck and Co.
The 1937 Marijuana Tax Act, driven by political and racial motivations during the prohibition era, effectively banned the substance. Cannabis was gradually removed from the pharmacopeia, and research was discouraged and eventually prohibited through federal drug scheduling. Federal authorities linked marijuana to insanity and claimed direct correlations between cannabis use, violence, and death — particularly targeting communities of color.
The Endocannabinoid System: A Biological Discovery That Changed Everything
Modern science did not discover endocannabinoids — cannabinoid compounds produced naturally by the human body — until 1990. These endogenous compounds function as a bio-regulatory mechanism for most major life processes and interact with receptor sites distributed throughout the body. CB2 receptors, found almost exclusively in the immune system with the highest concentration in the spleen, appear responsible for the anti-inflammatory and other significant therapeutic effects now attributed to cannabis.
CBD’s Unique Advantages Over Conventional Cancer Treatments
One of CBD’s most striking characteristics is its safety profile. Both CBD and THC can be administered in large doses without significant side effects. CBD has even demonstrated effectiveness as an antipsychotic medication when given at high doses. Perhaps most remarkably, CBD selectively targets and destroys tumor cells while leaving healthy cells unharmed — a stark contrast to chemotherapy and radiation, which are highly toxic and damage healthy tissue indiscriminately throughout the brain and body.
Industrial hemp, which is naturally high in CBD and very low in THC, represents a massive untapped resource. Hemp-derived CBD is typically discarded as a waste product, with tons thrown away annually that could instead be harvested for therapeutic applications including tumor reduction.
High-CBD Cannabis Strains: The Avidekel Breakthrough in Israel
The Israeli medical cannabis farm Tikun Olam developed a strain called Avidekel containing 15.8% CBD but only 1% THC — one of the highest CBD-to-THC ratios ever achieved in a cannabis variety. Zack Klein of Tikun Olam explained to Reuters that the psychoactive high is not always desirable or even pleasant for patients, making high-CBD, low-THC strains an important clinical option.
The THC vs. CBD Debate: Competition or Coexistence?
Some within the THC cannabis industry have expressed concern that rising CBD popularity could undermine the medical legitimacy of psychoactive cannabis products. However, THC carries its own well-documented medical benefits, and its capacity to reduce stress and improve mood should not be dismissed as therapeutically worthless. The most likely outcome is a diversified market where all varieties thrive — Indica, Sativa, combined CBD and THC formulations, and CBD-only products.
The Federal Government’s Own Cannabis Patent
In a notable contradiction to federal prohibition, the U.S. government has held a medical patent since 2003 for the marketing of cannabinoids as antioxidants and neuroprotective agents. The patent explicitly states that cannabinoids are useful in treating and preventing a wide variety of oxidation-associated diseases including inflammatory and autoimmune conditions, with particular application as neuroprotectants for stroke, trauma, Alzheimer’s disease, Parkinson’s disease, and HIV dementia.
Optimal Methods for Consuming Medical Cannabis
Research suggests that smoking cannabis is likely the least effective medicinal delivery method. According to researcher Pierre Desprez, it is unlikely that smoking alone delivers sufficient cannabidiol levels to impact diseases like cancer in a curative manner. The therapeutic potential of any cannabis strain depends largely on the ratio of its various cannabinoids, with evidence suggesting whole-spectrum formulations — including some THC — provide the greatest benefit.
Raw cannabis juicing, blended with carrots or leafy greens, has gained attention as a method of ingesting the acid forms of cannabinoids, which are non-psychoactive even when they include THC precursors. Cannabis oil extraction has also developed a dedicated following among patients who report significant therapeutic results including cancer remission.
Ancient Traditions of Raw Cannabis Consumption
In India, large populations continue the ancient practice of consuming Thandai, a fresh raw cannabis drink made by blending cannabis leaves into a paste with almonds, milk, and sugar. This traditional beverage appears at religious festivals, and some Indian cities maintain government-operated cannabis distribution points. A similar preparation called Bhang — a rolled sweet ball made with comparable ingredients — has been familiar to Western travelers visiting the ghats of sacred Varanasi for over a century.
The Future of Cannabis Edibles and CBD Products
Cannabis edibles represent one of the fastest-growing sectors in the food industry. Dispensaries across states with medical programs offer products ranging from ice cream and cough drops to peanut butter, honey, herbal teas, and an extensive variety of baked goods and savory snacks — all infused with THC.
Despite the enormous potential market for non-psychoactive cannabis, the introduction of CBD-rich products at the dispensary level has been surprisingly slow. Dispensary operators have been reluctant to stock CBD-dominant strains or edibles because their existing customer base generally seeks or accepts the euphoric and sedative effects of THC. As the medical benefits of non-psychoactive cannabis become more widely recognized, the variety and volume of CBD-rich foods and products entering the market will likely expand dramatically.
Restrictions on cannabis research have limited the precision with which medical professionals can prescribe cannabinoid therapies and determine the most effective delivery methods. The possibility remains that future cancer patients may consume raw non-psychoactive cannabis as a primary treatment — healing without enduring the collateral damage of radiation and chemotherapy.
